Lundbeck's Bocunebart Shows Promise in Migraine Prevention During AHS Congress 2026#Orlando#Denmark#Lundbeck#bocunebart#AHS_Congress
Lundbeck's Bocunebart Shows Promise in Migraine Prevention During AHS Congress 2026
At the AHS Congress 2026, Lundbeck unveiled positive Phase IIb results for bocunebart, indicating potential in migraine prevention for treatment-resistant patients.
third-news.com
June 4, 2026 at 9:11 PM
Lundbeck's Bocunebart Shows Promise in Migraine Prevention During AHS Congress 2026#Orlando#Denmark#Lundbeck#bocunebart#AHS_Congress